Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Myeloid, Acute | 306 | 2024 | 7061 | 20.270 |
Why?
|
Bridged Bicyclo Compounds, Heterocyclic | 86 | 2024 | 979 | 10.590 |
Why?
|
Sulfonamides | 97 | 2024 | 1896 | 9.550 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 70 | 2024 | 1515 | 6.300 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 150 | 2024 | 16258 | 5.960 |
Why?
|
Antineoplastic Agents | 123 | 2024 | 14501 | 5.650 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 71 | 2024 | 2847 | 5.460 |
Why?
|
fms-Like Tyrosine Kinase 3 | 48 | 2024 | 819 | 4.950 |
Why?
|
Apoptosis | 125 | 2023 | 7757 | 4.850 |
Why?
|
Hematologic Neoplasms | 33 | 2024 | 1919 | 3.900 |
Why?
|
Cytarabine | 56 | 2023 | 1993 | 3.810 |
Why?
|
Leukemia | 30 | 2024 | 1653 | 3.720 |
Why?
|
Protein Kinase Inhibitors | 71 | 2024 | 4884 | 3.500 |
Why?
|
Bone Marrow | 37 | 2021 | 2373 | 3.380 |
Why?
|
Azacitidine | 42 | 2024 | 1191 | 3.210 |
Why?
|
Drug Resistance, Neoplasm | 74 | 2024 | 5292 | 3.140 |
Why?
|
Leukemia, Myeloid | 25 | 2021 | 964 | 3.130 |
Why?
|
Philadelphia Chromosome | 35 | 2024 | 822 | 3.080 |
Why?
|
Oleanolic Acid | 25 | 2012 | 110 | 3.070 |
Why?
|
Neoplastic Stem Cells | 23 | 2022 | 1469 | 3.030 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 28 | 2024 | 495 | 3.010 |
Why?
|
Receptors, CXCR4 | 17 | 2019 | 273 | 2.870 |
Why?
|
Humans | 592 | 2024 | 270404 | 2.740 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 33 | 2023 | 2585 | 2.670 |
Why?
|
Myelodysplastic Syndromes | 41 | 2024 | 3063 | 2.570 |
Why?
|
Isocitrate Dehydrogenase | 18 | 2023 | 501 | 2.480 |
Why?
|
Dendritic Cells | 25 | 2024 | 1117 | 2.390 |
Why?
|
Biphenyl Compounds | 15 | 2021 | 194 | 2.350 |
Why?
|
Mutation | 97 | 2024 | 15577 | 2.230 |
Why?
|
Prodrugs | 7 | 2021 | 220 | 2.040 |
Why?
|
Neoplasm Proteins | 20 | 2021 | 3288 | 2.020 |
Why?
|
Nitrophenols | 14 | 2021 | 94 | 2.010 |
Why?
|
Aged | 226 | 2024 | 72800 | 1.990 |
Why?
|
Myeloproliferative Disorders | 15 | 2024 | 801 | 1.990 |
Why?
|
Tumor Microenvironment | 21 | 2024 | 2980 | 1.980 |
Why?
|
Hematopoietic Stem Cell Transplantation | 46 | 2024 | 6768 | 1.960 |
Why?
|
TOR Serine-Threonine Kinases | 16 | 2018 | 1559 | 1.950 |
Why?
|
Tumor Suppressor Protein p53 | 34 | 2024 | 3620 | 1.860 |
Why?
|
Cell Line, Tumor | 103 | 2024 | 14849 | 1.810 |
Why?
|
Molecular Targeted Therapy | 16 | 2024 | 2370 | 1.810 |
Why?
|
Interleukin-3 Receptor alpha Subunit | 15 | 2024 | 111 | 1.720 |
Why?
|
Fusion Proteins, bcr-abl | 24 | 2023 | 1126 | 1.700 |
Why?
|
Enzyme Inhibitors | 15 | 2021 | 1937 | 1.680 |
Why?
|
bcl-X Protein | 12 | 2023 | 199 | 1.670 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 13 | 2023 | 309 | 1.670 |
Why?
|
Middle Aged | 224 | 2024 | 89413 | 1.660 |
Why?
|
Myeloid Cell Leukemia Sequence 1 Protein | 20 | 2023 | 284 | 1.660 |
Why?
|
Adult | 210 | 2024 | 80581 | 1.650 |
Why?
|
Remission Induction | 52 | 2023 | 3621 | 1.640 |
Why?
|
Gene Expression Regulation, Leukemic | 29 | 2020 | 570 | 1.630 |
Why?
|
Aged, 80 and over | 127 | 2024 | 30767 | 1.580 |
Why?
|
Signal Transduction | 54 | 2024 | 12135 | 1.530 |
Why?
|
Blast Crisis | 18 | 2022 | 581 | 1.450 |
Why?
|
Animals | 131 | 2024 | 60938 | 1.430 |
Why?
|
Recombinant Fusion Proteins | 10 | 2024 | 1595 | 1.390 |
Why?
|
Imidazoles | 30 | 2024 | 1028 | 1.390 |
Why?
|
Mitochondria | 22 | 2022 | 1307 | 1.380 |
Why?
|
Hypoxia | 4 | 2016 | 455 | 1.360 |
Why?
|
Male | 225 | 2024 | 127406 | 1.350 |
Why?
|
Piperazines | 35 | 2021 | 2130 | 1.350 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 17 | 2023 | 518 | 1.340 |
Why?
|
Flow Cytometry | 31 | 2021 | 3071 | 1.330 |
Why?
|
Idarubicin | 17 | 2023 | 454 | 1.310 |
Why?
|
Phenylurea Compounds | 16 | 2024 | 598 | 1.300 |
Why?
|
Leukemia, Promyelocytic, Acute | 11 | 2021 | 439 | 1.290 |
Why?
|
Female | 231 | 2024 | 147053 | 1.270 |
Why?
|
Pyridines | 20 | 2022 | 1289 | 1.250 |
Why?
|
Proto-Oncogene Proteins c-akt | 20 | 2021 | 2084 | 1.220 |
Why?
|
Young Adult | 99 | 2023 | 22096 | 1.220 |
Why?
|
Receptors, Cytokine | 9 | 2023 | 180 | 1.220 |
Why?
|
Chemokine CXCL12 | 11 | 2019 | 132 | 1.210 |
Why?
|
Mice | 103 | 2024 | 35283 | 1.210 |
Why?
|
Mice, Inbred NOD | 22 | 2021 | 902 | 1.200 |
Why?
|
Pyrimidines | 24 | 2021 | 3603 | 1.190 |
Why?
|
Hematopoietic Stem Cells | 12 | 2022 | 1266 | 1.180 |
Why?
|
Salvage Therapy | 15 | 2021 | 2095 | 1.180 |
Why?
|
Pyridazines | 11 | 2024 | 306 | 1.150 |
Why?
|
Oxidative Phosphorylation | 5 | 2023 | 258 | 1.140 |
Why?
|
Nitroimidazoles | 3 | 2016 | 105 | 1.140 |
Why?
|
Fatty Acids | 4 | 2018 | 459 | 1.130 |
Why?
|
Glutamine | 5 | 2022 | 303 | 1.120 |
Why?
|
Recurrence | 35 | 2024 | 4873 | 1.120 |
Why?
|
Mice, SCID | 25 | 2021 | 1864 | 1.120 |
Why?
|
Acute Disease | 31 | 2023 | 2469 | 1.080 |
Why?
|
Niacinamide | 13 | 2015 | 423 | 1.080 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 5 | 2017 | 395 | 1.070 |
Why?
|
Phosphoramide Mustards | 2 | 2016 | 37 | 1.070 |
Why?
|
Proteomics | 6 | 2022 | 1422 | 1.070 |
Why?
|
Azetidines | 2 | 2024 | 91 | 1.060 |
Why?
|
Antibodies, Bispecific | 9 | 2023 | 266 | 1.060 |
Why?
|
Treatment Outcome | 94 | 2024 | 34163 | 1.050 |
Why?
|
Dancing | 2 | 2022 | 22 | 1.050 |
Why?
|
PPAR gamma | 7 | 2010 | 231 | 1.040 |
Why?
|
U937 Cells | 19 | 2019 | 172 | 1.030 |
Why?
|
Neoplasm, Residual | 23 | 2023 | 1716 | 1.030 |
Why?
|
Cell Proliferation | 42 | 2021 | 7300 | 1.020 |
Why?
|
Antigens, CD | 8 | 2023 | 1409 | 1.020 |
Why?
|
Coculture Techniques | 13 | 2020 | 632 | 1.020 |
Why?
|
Skin Neoplasms | 14 | 2024 | 4775 | 1.010 |
Why?
|
Antimetabolites, Antineoplastic | 16 | 2021 | 1329 | 1.000 |
Why?
|
Prognosis | 72 | 2024 | 22228 | 0.990 |
Why?
|
Xenograft Model Antitumor Assays | 28 | 2024 | 3930 | 0.990 |
Why?
|
Piperidines | 7 | 2024 | 1067 | 0.990 |
Why?
|
Nitrogen Mustard Compounds | 3 | 2015 | 73 | 0.990 |
Why?
|
Tumor Cells, Cultured | 37 | 2021 | 5509 | 0.980 |
Why?
|
Apoptosis Regulatory Proteins | 9 | 2022 | 628 | 0.970 |
Why?
|
Phosphorylation | 40 | 2019 | 4885 | 0.960 |
Why?
|
Cell Survival | 30 | 2021 | 3061 | 0.960 |
Why?
|
Stromal Cells | 12 | 2019 | 831 | 0.960 |
Why?
|
Drug Delivery Systems | 6 | 2018 | 682 | 0.950 |
Why?
|
Morpholines | 8 | 2017 | 293 | 0.950 |
Why?
|
Heterocyclic Compounds | 5 | 2020 | 121 | 0.940 |
Why?
|
Vidarabine | 12 | 2022 | 1362 | 0.930 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 10 | 2022 | 472 | 0.930 |
Why?
|
Vincristine | 24 | 2022 | 1532 | 0.920 |
Why?
|
Disease-Free Survival | 48 | 2023 | 10092 | 0.890 |
Why?
|
Cyclophosphamide | 26 | 2022 | 3143 | 0.890 |
Why?
|
Cell Differentiation | 21 | 2024 | 4165 | 0.890 |
Why?
|
Transplantation Conditioning | 7 | 2021 | 2301 | 0.880 |
Why?
|
Adipocytes | 5 | 2018 | 312 | 0.880 |
Why?
|
Thrombocytopenia | 5 | 2021 | 872 | 0.880 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 7 | 2023 | 215 | 0.870 |
Why?
|
Bone Marrow Cells | 14 | 2021 | 928 | 0.870 |
Why?
|
Dexamethasone | 24 | 2022 | 1471 | 0.860 |
Why?
|
Programmed Cell Death 1 Receptor | 4 | 2023 | 1069 | 0.860 |
Why?
|
Oncogene Proteins, Fusion | 11 | 2020 | 779 | 0.860 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 6 | 2021 | 203 | 0.840 |
Why?
|
Granulocyte Colony-Stimulating Factor | 7 | 2022 | 759 | 0.820 |
Why?
|
Neoplasm Recurrence, Local | 21 | 2023 | 10254 | 0.820 |
Why?
|
HL-60 Cells | 19 | 2021 | 306 | 0.810 |
Why?
|
Leukemia, Myeloid, Chronic-Phase | 6 | 2020 | 524 | 0.810 |
Why?
|
Transplantation, Homologous | 13 | 2023 | 2941 | 0.810 |
Why?
|
Proto-Oncogene Proteins | 16 | 2021 | 2547 | 0.800 |
Why?
|
Hematopoietic Stem Cell Mobilization | 3 | 2019 | 267 | 0.800 |
Why?
|
Drug Synergism | 25 | 2019 | 1336 | 0.790 |
Why?
|
Benzamides | 19 | 2017 | 1873 | 0.790 |
Why?
|
Indazoles | 3 | 2013 | 302 | 0.780 |
Why?
|
Stem Cell Niche | 3 | 2017 | 91 | 0.780 |
Why?
|
Leukemia, Experimental | 3 | 2016 | 78 | 0.780 |
Why?
|
Adolescent | 78 | 2024 | 32250 | 0.770 |
Why?
|
Aniline Compounds | 6 | 2024 | 195 | 0.770 |
Why?
|
Survival Analysis | 40 | 2021 | 9320 | 0.770 |
Why?
|
Kaplan-Meier Estimate | 26 | 2021 | 6265 | 0.750 |
Why?
|
Immune Evasion | 1 | 2021 | 77 | 0.750 |
Why?
|
Imatinib Mesylate | 15 | 2019 | 1687 | 0.750 |
Why?
|
Dasatinib | 11 | 2023 | 877 | 0.740 |
Why?
|
Transcription Factors | 17 | 2023 | 5357 | 0.740 |
Why?
|
Benzeneacetamides | 2 | 2019 | 28 | 0.740 |
Why?
|
Nuclear Proteins | 15 | 2023 | 3383 | 0.730 |
Why?
|
Thiadiazoles | 2 | 2019 | 47 | 0.730 |
Why?
|
Glutaminase | 2 | 2019 | 49 | 0.730 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2021 | 131 | 0.720 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 8 | 2022 | 383 | 0.710 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2021 | 203 | 0.710 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 6 | 2022 | 450 | 0.700 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 12 | 2023 | 2425 | 0.700 |
Why?
|
Drug Administration Schedule | 19 | 2021 | 3518 | 0.700 |
Why?
|
Myelitis, Transverse | 1 | 2019 | 13 | 0.690 |
Why?
|
Intervertebral Disc Degeneration | 1 | 2019 | 22 | 0.680 |
Why?
|
Doxorubicin | 28 | 2022 | 3059 | 0.680 |
Why?
|
B-Lymphocytes | 11 | 2023 | 1347 | 0.670 |
Why?
|
Gene Rearrangement | 9 | 2023 | 797 | 0.670 |
Why?
|
Retrospective Studies | 68 | 2024 | 39440 | 0.660 |
Why?
|
MAP Kinase Signaling System | 10 | 2022 | 885 | 0.660 |
Why?
|
Optic Neuritis | 1 | 2019 | 39 | 0.650 |
Why?
|
Oxidoreductases Acting on CH-CH Group Donors | 1 | 2018 | 13 | 0.650 |
Why?
|
Pyrroles | 4 | 2022 | 594 | 0.650 |
Why?
|
Induction Chemotherapy | 15 | 2023 | 666 | 0.640 |
Why?
|
Survival Rate | 40 | 2024 | 12428 | 0.640 |
Why?
|
Blotting, Western | 21 | 2015 | 3595 | 0.630 |
Why?
|
Proto-Oncogene Proteins c-pim-1 | 2 | 2015 | 45 | 0.620 |
Why?
|
Neoplasms | 10 | 2023 | 15695 | 0.620 |
Why?
|
Receptors, Interleukin-3 | 2 | 2014 | 26 | 0.610 |
Why?
|
Arabinonucleosides | 8 | 2021 | 447 | 0.610 |
Why?
|
DNA Modification Methylases | 2 | 2022 | 173 | 0.610 |
Why?
|
Indoles | 5 | 2019 | 1021 | 0.590 |
Why?
|
Histone Deacetylase Inhibitors | 6 | 2023 | 620 | 0.590 |
Why?
|
Cell Cycle | 18 | 2018 | 2114 | 0.580 |
Why?
|
Tumor Hypoxia | 1 | 2017 | 24 | 0.580 |
Why?
|
Connective Tissue Growth Factor | 2 | 2013 | 43 | 0.560 |
Why?
|
Sulfides | 1 | 2016 | 48 | 0.560 |
Why?
|
Genomics | 7 | 2022 | 2818 | 0.560 |
Why?
|
Histone Demethylases | 1 | 2018 | 147 | 0.560 |
Why?
|
Dose-Response Relationship, Drug | 23 | 2019 | 5028 | 0.560 |
Why?
|
Graft vs Host Disease | 11 | 2024 | 2718 | 0.560 |
Why?
|
Cladribine | 7 | 2023 | 252 | 0.540 |
Why?
|
Propensity Score | 7 | 2022 | 784 | 0.540 |
Why?
|
Benzoxazoles | 1 | 2016 | 40 | 0.540 |
Why?
|
Genes, bcl-2 | 5 | 2015 | 168 | 0.540 |
Why?
|
DNA Methylation | 11 | 2021 | 2733 | 0.540 |
Why?
|
Energy Metabolism | 5 | 2019 | 1007 | 0.540 |
Why?
|
Amino Acids | 1 | 2019 | 759 | 0.540 |
Why?
|
Thiazolidines | 1 | 2015 | 15 | 0.530 |
Why?
|
Busulfan | 3 | 2020 | 778 | 0.530 |
Why?
|
Aminopyridines | 5 | 2022 | 219 | 0.530 |
Why?
|
Carnitine O-Palmitoyltransferase | 1 | 2015 | 28 | 0.530 |
Why?
|
Stem Cell Transplantation | 9 | 2023 | 1384 | 0.520 |
Why?
|
Models, Biological | 7 | 2020 | 3254 | 0.520 |
Why?
|
Asparaginase | 8 | 2024 | 186 | 0.520 |
Why?
|
Antineoplastic Agents, Immunological | 8 | 2024 | 1313 | 0.520 |
Why?
|
Benzimidazoles | 5 | 2021 | 438 | 0.510 |
Why?
|
Antibodies, Monoclonal, Humanized | 12 | 2021 | 3361 | 0.510 |
Why?
|
Carnitine | 1 | 2015 | 93 | 0.500 |
Why?
|
Fetal Blood | 4 | 2021 | 479 | 0.500 |
Why?
|
Methyltransferases | 3 | 2022 | 149 | 0.490 |
Why?
|
Cell Cycle Proteins | 11 | 2023 | 2099 | 0.490 |
Why?
|
Antibodies, Monoclonal | 7 | 2022 | 4442 | 0.490 |
Why?
|
T-Lymphocytes | 15 | 2024 | 3955 | 0.490 |
Why?
|
Benzylamines | 5 | 2020 | 103 | 0.490 |
Why?
|
Histone-Lysine N-Methyltransferase | 5 | 2021 | 462 | 0.490 |
Why?
|
Peptides, Cyclic | 1 | 2015 | 138 | 0.480 |
Why?
|
Protein-Tyrosine Kinases | 10 | 2021 | 1787 | 0.480 |
Why?
|
Pyrazoles | 6 | 2021 | 1517 | 0.470 |
Why?
|
DNA-Binding Proteins | 10 | 2023 | 4906 | 0.470 |
Why?
|
Follow-Up Studies | 31 | 2021 | 15182 | 0.470 |
Why?
|
Antigens, CD34 | 12 | 2019 | 591 | 0.460 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2015 | 595 | 0.460 |
Why?
|
Unrelated Donors | 3 | 2024 | 322 | 0.450 |
Why?
|
Transforming Growth Factor beta1 | 2 | 2020 | 306 | 0.440 |
Why?
|
Febrile Neutropenia | 3 | 2024 | 71 | 0.440 |
Why?
|
Tandem Repeat Sequences | 7 | 2020 | 202 | 0.440 |
Why?
|
Sialic Acid Binding Ig-like Lectin 3 | 3 | 2024 | 88 | 0.440 |
Why?
|
Cell Movement | 7 | 2019 | 2498 | 0.440 |
Why?
|
Triazines | 4 | 2022 | 117 | 0.440 |
Why?
|
para-Aminobenzoates | 3 | 2022 | 10 | 0.430 |
Why?
|
Caspases | 11 | 2011 | 685 | 0.430 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2014 | 151 | 0.430 |
Why?
|
Benzenesulfonates | 6 | 2012 | 196 | 0.430 |
Why?
|
Primary Myelofibrosis | 4 | 2024 | 878 | 0.430 |
Why?
|
Daunorubicin | 5 | 2021 | 304 | 0.420 |
Why?
|
Purines | 2 | 2023 | 275 | 0.420 |
Why?
|
Immunoconjugates | 3 | 2024 | 302 | 0.420 |
Why?
|
Carcinogenesis | 3 | 2021 | 1048 | 0.410 |
Why?
|
Pyrrolidines | 3 | 2022 | 113 | 0.410 |
Why?
|
Gossypol | 3 | 2017 | 28 | 0.400 |
Why?
|
Alleles | 7 | 2020 | 2479 | 0.400 |
Why?
|
Benzoates | 2 | 2019 | 133 | 0.390 |
Why?
|
Janus Kinase 2 | 5 | 2023 | 686 | 0.390 |
Why?
|
Membrane Microdomains | 1 | 2011 | 84 | 0.390 |
Why?
|
Sirolimus | 5 | 2022 | 834 | 0.380 |
Why?
|
Neoplasms, Second Primary | 4 | 2022 | 1377 | 0.380 |
Why?
|
Lymphoma, Mantle-Cell | 6 | 2017 | 736 | 0.380 |
Why?
|
Histocompatibility Testing | 3 | 2024 | 465 | 0.370 |
Why?
|
Cell Division | 15 | 2008 | 2554 | 0.370 |
Why?
|
Cell Communication | 4 | 2009 | 506 | 0.370 |
Why?
|
Adenine Nucleotides | 5 | 2017 | 360 | 0.370 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 7 | 2017 | 598 | 0.370 |
Why?
|
Mediator Complex Subunit 1 | 1 | 2010 | 8 | 0.370 |
Why?
|
RNA, Messenger | 16 | 2016 | 6222 | 0.370 |
Why?
|
Receptors, Immunologic | 3 | 2023 | 317 | 0.360 |
Why?
|
Lymphoma, B-Cell | 4 | 2023 | 917 | 0.360 |
Why?
|
Enzyme Activation | 15 | 2015 | 1798 | 0.360 |
Why?
|
Tretinoin | 11 | 2021 | 637 | 0.360 |
Why?
|
Clonal Evolution | 3 | 2020 | 252 | 0.360 |
Why?
|
Cells, Cultured | 13 | 2021 | 5663 | 0.360 |
Why?
|
Autophagy | 4 | 2023 | 930 | 0.350 |
Why?
|
Multiprotein Complexes | 1 | 2012 | 387 | 0.350 |
Why?
|
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 3 | 2021 | 120 | 0.350 |
Why?
|
bcl-2-Associated X Protein | 9 | 2022 | 371 | 0.350 |
Why?
|
src-Family Kinases | 2 | 2014 | 480 | 0.350 |
Why?
|
Gene Expression Profiling | 14 | 2021 | 5239 | 0.350 |
Why?
|
Carrier Proteins | 7 | 2017 | 2054 | 0.350 |
Why?
|
NAD+ Nucleosidase | 2 | 2000 | 17 | 0.340 |
Why?
|
Maximum Tolerated Dose | 10 | 2021 | 1314 | 0.340 |
Why?
|
Biomarkers, Tumor | 16 | 2021 | 10623 | 0.340 |
Why?
|
Chromosome Aberrations | 9 | 2022 | 1978 | 0.340 |
Why?
|
Triazoles | 4 | 2021 | 630 | 0.340 |
Why?
|
Methotrexate | 6 | 2022 | 1022 | 0.340 |
Why?
|
Transplantation, Haploidentical | 3 | 2019 | 155 | 0.330 |
Why?
|
Membrane Proteins | 7 | 2014 | 2914 | 0.330 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 11 | 2015 | 3664 | 0.330 |
Why?
|
Gene Expression | 12 | 2016 | 3593 | 0.330 |
Why?
|
Immunosuppressive Agents | 3 | 2022 | 1425 | 0.330 |
Why?
|
Nitriles | 6 | 2021 | 935 | 0.330 |
Why?
|
Disease Management | 4 | 2022 | 1105 | 0.320 |
Why?
|
Pyrazines | 4 | 2024 | 508 | 0.320 |
Why?
|
Administration, Oral | 7 | 2019 | 1581 | 0.320 |
Why?
|
Protein Binding | 8 | 2021 | 3479 | 0.320 |
Why?
|
Antigens, Differentiation | 2 | 2000 | 247 | 0.310 |
Why?
|
Proportional Hazards Models | 11 | 2021 | 5113 | 0.310 |
Why?
|
Allografts | 6 | 2022 | 679 | 0.310 |
Why?
|
Pneumonia | 3 | 2023 | 759 | 0.310 |
Why?
|
Lactic Acid | 3 | 2019 | 310 | 0.310 |
Why?
|
Phosphatidylinositol 3-Kinases | 5 | 2023 | 1706 | 0.310 |
Why?
|
Membrane Glycoproteins | 8 | 2021 | 1098 | 0.310 |
Why?
|
Genes, ras | 4 | 2022 | 672 | 0.310 |
Why?
|
ras Proteins | 4 | 2022 | 783 | 0.310 |
Why?
|
Gene Frequency | 4 | 2021 | 1181 | 0.310 |
Why?
|
Translocation, Genetic | 8 | 2023 | 1269 | 0.300 |
Why?
|
AMP-Activated Protein Kinases | 4 | 2019 | 409 | 0.300 |
Why?
|
Stem Cells | 5 | 2022 | 1244 | 0.300 |
Why?
|
Immunophenotyping | 7 | 2021 | 1700 | 0.300 |
Why?
|
Benzothiazoles | 3 | 2024 | 103 | 0.300 |
Why?
|
Dioxygenases | 3 | 2023 | 165 | 0.300 |
Why?
|
Consolidation Chemotherapy | 5 | 2020 | 156 | 0.300 |
Why?
|
Transforming Growth Factor beta | 1 | 2013 | 1141 | 0.300 |
Why?
|
Burkitt Lymphoma | 4 | 2023 | 344 | 0.300 |
Why?
|
Adenylate Kinase | 2 | 2018 | 35 | 0.290 |
Why?
|
Peptide Fragments | 5 | 2017 | 1294 | 0.290 |
Why?
|
Cytokines | 5 | 2022 | 2867 | 0.290 |
Why?
|
Disease Susceptibility | 2 | 2020 | 546 | 0.290 |
Why?
|
Annexin A1 | 1 | 2007 | 40 | 0.290 |
Why?
|
NF-kappa B | 6 | 2021 | 1584 | 0.290 |
Why?
|
Activating Transcription Factor 4 | 2 | 2018 | 78 | 0.290 |
Why?
|
Cell Line | 12 | 2023 | 5126 | 0.290 |
Why?
|
Transplantation, Heterologous | 6 | 2014 | 1091 | 0.290 |
Why?
|
Cell Hypoxia | 3 | 2012 | 335 | 0.290 |
Why?
|
Glycolysis | 4 | 2021 | 530 | 0.290 |
Why?
|
Oxidation-Reduction | 5 | 2018 | 729 | 0.280 |
Why?
|
Cohort Studies | 14 | 2024 | 9476 | 0.280 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2008 | 231 | 0.280 |
Why?
|
Neoplasm Transplantation | 7 | 2019 | 1532 | 0.280 |
Why?
|
Polymorphism, Single Nucleotide | 6 | 2020 | 4639 | 0.280 |
Why?
|
Oligodeoxyribonucleotides, Antisense | 2 | 2001 | 43 | 0.280 |
Why?
|
Protein Kinases | 3 | 2008 | 888 | 0.280 |
Why?
|
raf Kinases | 2 | 2007 | 81 | 0.280 |
Why?
|
Cell Transformation, Neoplastic | 5 | 2019 | 2395 | 0.280 |
Why?
|
Anemia | 3 | 2020 | 726 | 0.280 |
Why?
|
Genes, p53 | 5 | 2017 | 1122 | 0.280 |
Why?
|
Reactive Oxygen Species | 13 | 2021 | 1005 | 0.270 |
Why?
|
Sialic Acid Binding Ig-like Lectin 2 | 2 | 2024 | 60 | 0.270 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 4 | 2020 | 343 | 0.270 |
Why?
|
Janus Kinases | 4 | 2023 | 177 | 0.270 |
Why?
|
Prospective Studies | 20 | 2022 | 13269 | 0.270 |
Why?
|
Cell Death | 4 | 2018 | 675 | 0.270 |
Why?
|
Protein Array Analysis | 4 | 2019 | 504 | 0.270 |
Why?
|
Mechanistic Target of Rapamycin Complex 1 | 3 | 2021 | 271 | 0.270 |
Why?
|
Clinical Trials as Topic | 8 | 2022 | 3836 | 0.270 |
Why?
|
Disease Models, Animal | 13 | 2024 | 7414 | 0.270 |
Why?
|
Proteins | 5 | 2021 | 1984 | 0.270 |
Why?
|
Interferon-alpha | 4 | 2022 | 904 | 0.270 |
Why?
|
Karyotype | 6 | 2024 | 236 | 0.260 |
Why?
|
Transcriptome | 10 | 2023 | 1951 | 0.260 |
Why?
|
Antifungal Agents | 4 | 2021 | 854 | 0.260 |
Why?
|
Prostaglandin D2 | 2 | 2004 | 28 | 0.260 |
Why?
|
Heterografts | 6 | 2020 | 749 | 0.260 |
Why?
|
Age Factors | 14 | 2021 | 5490 | 0.260 |
Why?
|
Biomimetics | 3 | 2017 | 35 | 0.260 |
Why?
|
Gene Expression Regulation, Neoplastic | 10 | 2021 | 9064 | 0.260 |
Why?
|
PAX5 Transcription Factor | 3 | 2022 | 45 | 0.260 |
Why?
|
MAP Kinase Kinase 1 | 2 | 2019 | 164 | 0.250 |
Why?
|
Single-Cell Analysis | 5 | 2021 | 523 | 0.250 |
Why?
|
Quinolines | 2 | 2021 | 396 | 0.250 |
Why?
|
Mycoses | 2 | 2021 | 386 | 0.250 |
Why?
|
Protein Phosphatase 2 | 4 | 2014 | 88 | 0.240 |
Why?
|
Retinoid X Receptors | 1 | 2004 | 86 | 0.240 |
Why?
|
Caveolin 1 | 1 | 2006 | 207 | 0.240 |
Why?
|
MAP Kinase Kinase Kinases | 2 | 2017 | 195 | 0.240 |
Why?
|
Chromosomes, Human, Pair 7 | 2 | 2022 | 231 | 0.240 |
Why?
|
Oxadiazoles | 2 | 2021 | 60 | 0.240 |
Why?
|
Single-Domain Antibodies | 1 | 2024 | 15 | 0.240 |
Why?
|
Enhancer Elements, Genetic | 2 | 2017 | 470 | 0.240 |
Why?
|
bcl-2 Homologous Antagonist-Killer Protein | 5 | 2011 | 72 | 0.240 |
Why?
|
Up-Regulation | 8 | 2023 | 2480 | 0.240 |
Why?
|
Repressor Proteins | 5 | 2023 | 1698 | 0.230 |
Why?
|
High-Throughput Nucleotide Sequencing | 10 | 2022 | 2340 | 0.230 |
Why?
|
Uridine | 1 | 2024 | 61 | 0.230 |
Why?
|
Myeloid Progenitor Cells | 3 | 2021 | 47 | 0.230 |
Why?
|
Chromosome Inversion | 2 | 2023 | 183 | 0.230 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2023 | 1701 | 0.230 |
Why?
|
Risk Factors | 17 | 2021 | 18229 | 0.230 |
Why?
|
Lymphoma | 4 | 2016 | 1495 | 0.230 |
Why?
|
Receptors, Cell Surface | 4 | 2023 | 877 | 0.220 |
Why?
|
Patient Safety | 3 | 2018 | 675 | 0.220 |
Why?
|
Glycine | 3 | 2021 | 305 | 0.220 |
Why?
|
Anemia, Refractory | 1 | 2003 | 39 | 0.220 |
Why?
|
Isoflavones | 1 | 2023 | 74 | 0.220 |
Why?
|
Cytogenetic Analysis | 2 | 2021 | 572 | 0.220 |
Why?
|
Mass Spectrometry | 2 | 2017 | 717 | 0.220 |
Why?
|
Neoadjuvant Therapy | 2 | 2017 | 5105 | 0.220 |
Why?
|
Hypoglycemic Agents | 4 | 2012 | 609 | 0.220 |
Why?
|
Mercaptopurine | 3 | 2021 | 130 | 0.220 |
Why?
|
Leukemia, B-Cell | 2 | 2021 | 114 | 0.220 |
Why?
|
Arsenicals | 2 | 2021 | 201 | 0.220 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2020 | 679 | 0.220 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2023 | 187 | 0.220 |
Why?
|
Thalidomide | 3 | 2019 | 577 | 0.210 |
Why?
|
Leukemia, Megakaryoblastic, Acute | 1 | 2023 | 44 | 0.210 |
Why?
|
Asparagine | 2 | 2019 | 39 | 0.210 |
Why?
|
Heterocyclic Compounds, 4 or More Rings | 3 | 2016 | 125 | 0.210 |
Why?
|
Tumor Burden | 5 | 2021 | 2018 | 0.210 |
Why?
|
Mast Cells | 1 | 2024 | 230 | 0.210 |
Why?
|
STAT3 Transcription Factor | 5 | 2017 | 1138 | 0.210 |
Why?
|
Child | 18 | 2024 | 30092 | 0.210 |
Why?
|
Nucleosides | 1 | 2022 | 61 | 0.210 |
Why?
|
Cigarette Smoking | 1 | 2023 | 98 | 0.210 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2023 | 107 | 0.210 |
Why?
|
Biomarkers | 8 | 2023 | 5171 | 0.210 |
Why?
|
Gene Silencing | 3 | 2018 | 838 | 0.210 |
Why?
|
Cellular Microenvironment | 2 | 2012 | 41 | 0.210 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2021 | 163 | 0.210 |
Why?
|
c-Mer Tyrosine Kinase | 1 | 2022 | 28 | 0.210 |
Why?
|
Organic Chemicals | 1 | 2002 | 111 | 0.210 |
Why?
|
Leukemia, Monocytic, Acute | 2 | 2017 | 31 | 0.210 |
Why?
|
GATA3 Transcription Factor | 2 | 2020 | 147 | 0.210 |
Why?
|
Bcl-2-Like Protein 11 | 5 | 2016 | 69 | 0.210 |
Why?
|
Diphenylamine | 2 | 2012 | 15 | 0.210 |
Why?
|
THP-1 Cells | 2 | 2019 | 55 | 0.200 |
Why?
|
Biomimetic Materials | 1 | 2022 | 41 | 0.200 |
Why?
|
Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2023 | 88 | 0.200 |
Why?
|
Immunotherapy, Adoptive | 2 | 2023 | 1890 | 0.200 |
Why?
|
B-Cell Activating Factor | 1 | 2021 | 25 | 0.200 |
Why?
|
Drug Combinations | 1 | 2024 | 635 | 0.200 |
Why?
|
Thrombocythemia, Essential | 2 | 2017 | 163 | 0.200 |
Why?
|
Mice, Knockout | 7 | 2021 | 5794 | 0.200 |
Why?
|
Interferon-gamma | 2 | 2024 | 1162 | 0.200 |
Why?
|
Homeodomain Proteins | 3 | 2015 | 1149 | 0.200 |
Why?
|
Monomeric GTP-Binding Proteins | 1 | 2021 | 46 | 0.200 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2006 | 675 | 0.200 |
Why?
|
Drug Therapy, Combination | 6 | 2021 | 2344 | 0.200 |
Why?
|
Cysteine | 2 | 2019 | 214 | 0.200 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2020 | 474 | 0.200 |
Why?
|
Mice, Transgenic | 8 | 2021 | 4228 | 0.190 |
Why?
|
Cellular Senescence | 1 | 2023 | 386 | 0.190 |
Why?
|
Ribonucleoproteins | 1 | 2021 | 122 | 0.190 |
Why?
|
Receptors, Notch | 2 | 2019 | 385 | 0.190 |
Why?
|
Polycythemia Vera | 2 | 2017 | 240 | 0.190 |
Why?
|
Azoles | 1 | 2021 | 48 | 0.190 |
Why?
|
Mitochondrial Dynamics | 1 | 2021 | 69 | 0.190 |
Why?
|
Cellular Reprogramming Techniques | 1 | 2021 | 31 | 0.190 |
Why?
|
Suppressor of Cytokine Signaling Proteins | 1 | 2021 | 61 | 0.190 |
Why?
|
Oxidoreductases Acting on CH-NH Group Donors | 1 | 2020 | 31 | 0.190 |
Why?
|
Hematology | 1 | 2022 | 99 | 0.190 |
Why?
|
Membrane Potentials | 5 | 2005 | 435 | 0.190 |
Why?
|
Ribosomal Protein S6 Kinases, 70-kDa | 3 | 2012 | 131 | 0.190 |
Why?
|
Jurkat Cells | 3 | 2006 | 315 | 0.190 |
Why?
|
Lectins, C-Type | 1 | 2021 | 164 | 0.190 |
Why?
|
Pyruvic Acid | 2 | 2019 | 134 | 0.190 |
Why?
|
Tumor Lysis Syndrome | 1 | 2020 | 37 | 0.180 |
Why?
|
Peptides | 1 | 2006 | 1503 | 0.180 |
Why?
|
Immunoglobulin Variable Region | 1 | 2021 | 173 | 0.180 |
Why?
|
Sarcoma, Myeloid | 1 | 2021 | 93 | 0.180 |
Why?
|
Histones | 5 | 2019 | 1493 | 0.180 |
Why?
|
Drug Evaluation | 1 | 2020 | 427 | 0.180 |
Why?
|
SEER Program | 1 | 2024 | 1012 | 0.180 |
Why?
|
Caspase 8 | 5 | 2015 | 148 | 0.180 |
Why?
|
Phosphoproteins | 3 | 2015 | 1177 | 0.180 |
Why?
|
Child, Preschool | 10 | 2021 | 16732 | 0.180 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2021 | 127 | 0.180 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2020 | 2733 | 0.180 |
Why?
|
MicroRNAs | 5 | 2014 | 2954 | 0.180 |
Why?
|
RNA, Small Interfering | 6 | 2017 | 2221 | 0.180 |
Why?
|
Respiratory Insufficiency | 1 | 2024 | 348 | 0.180 |
Why?
|
Aminoglycosides | 3 | 2016 | 224 | 0.180 |
Why?
|
ADP-ribosyl Cyclase 1 | 5 | 2019 | 141 | 0.180 |
Why?
|
Phenotype | 6 | 2019 | 6395 | 0.180 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2021 | 247 | 0.180 |
Why?
|
Combined Modality Therapy | 7 | 2021 | 9002 | 0.180 |
Why?
|
Proto-Oncogene Proteins c-abl | 1 | 2020 | 81 | 0.180 |
Why?
|
Real-Time Polymerase Chain Reaction | 2 | 2015 | 1232 | 0.180 |
Why?
|
Oxygen | 2 | 2019 | 778 | 0.180 |
Why?
|
Acetyl Coenzyme A | 1 | 2019 | 23 | 0.180 |
Why?
|
Protein Isoforms | 4 | 2016 | 849 | 0.180 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 2 | 2024 | 608 | 0.180 |
Why?
|
Gene Expression Regulation | 4 | 2021 | 4066 | 0.180 |
Why?
|
Glucose | 3 | 2017 | 1267 | 0.170 |
Why?
|
Polyethylene Glycols | 2 | 2017 | 637 | 0.170 |
Why?
|
Killer Cells, Natural | 3 | 2022 | 931 | 0.170 |
Why?
|
Autoimmunity | 1 | 2021 | 275 | 0.170 |
Why?
|
Multivariate Analysis | 7 | 2021 | 4383 | 0.170 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2021 | 188 | 0.170 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2021 | 1168 | 0.170 |
Why?
|
Retreatment | 5 | 2020 | 452 | 0.170 |
Why?
|
Transcription Factor 4 | 1 | 2019 | 36 | 0.170 |
Why?
|
Interleukin-15 | 1 | 2021 | 188 | 0.170 |
Why?
|
Epigenomics | 2 | 2021 | 268 | 0.170 |
Why?
|
Capillary Leak Syndrome | 1 | 2019 | 14 | 0.170 |
Why?
|
Aspartate-Ammonia Ligase | 1 | 2019 | 23 | 0.170 |
Why?
|
Pteridines | 1 | 2019 | 34 | 0.170 |
Why?
|
Cyclin-Dependent Kinase 9 | 1 | 2019 | 69 | 0.170 |
Why?
|
T-Lymphocyte Subsets | 2 | 2021 | 592 | 0.170 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2014 | 717 | 0.170 |
Why?
|
Bortezomib | 3 | 2017 | 549 | 0.170 |
Why?
|
MAP Kinase Kinase 2 | 1 | 2019 | 45 | 0.170 |
Why?
|
Point Mutation | 3 | 2019 | 774 | 0.170 |
Why?
|
Antigens, CD19 | 4 | 2023 | 586 | 0.170 |
Why?
|
B7-H1 Antigen | 2 | 2023 | 1057 | 0.170 |
Why?
|
Immunologic Factors | 3 | 2017 | 667 | 0.170 |
Why?
|
Cell Culture Techniques | 2 | 2019 | 595 | 0.170 |
Why?
|
Antibiotics, Antineoplastic | 4 | 2013 | 734 | 0.160 |
Why?
|
Central Nervous System | 1 | 2021 | 449 | 0.160 |
Why?
|
Blood Component Transfusion | 1 | 2019 | 93 | 0.160 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2020 | 319 | 0.160 |
Why?
|
Risk | 2 | 2020 | 1998 | 0.160 |
Why?
|
Receptors, Retinoic Acid | 5 | 2007 | 368 | 0.160 |
Why?
|
Microscopy, Fluorescence, Multiphoton | 1 | 2019 | 61 | 0.160 |
Why?
|
Methylation | 2 | 2017 | 599 | 0.160 |
Why?
|
Cellular Reprogramming | 1 | 2021 | 201 | 0.160 |
Why?
|
Multienzyme Complexes | 1 | 2000 | 222 | 0.160 |
Why?
|
Hematopoiesis | 3 | 2009 | 565 | 0.160 |
Why?
|
Leukemic Infiltration | 1 | 2018 | 73 | 0.160 |
Why?
|
Risk Assessment | 6 | 2022 | 7162 | 0.160 |
Why?
|
Patient Dropouts | 1 | 2019 | 91 | 0.160 |
Why?
|
Electron Transport | 2 | 2016 | 83 | 0.160 |
Why?
|
Sepsis | 1 | 2024 | 667 | 0.160 |
Why?
|
Structure-Activity Relationship | 1 | 2020 | 963 | 0.160 |
Why?
|
Pilot Projects | 3 | 2020 | 2857 | 0.160 |
Why?
|
Interferon Inducers | 1 | 2017 | 10 | 0.150 |
Why?
|
Leukemia, Biphenotypic, Acute | 1 | 2018 | 51 | 0.150 |
Why?
|
GRB2 Adaptor Protein | 1 | 2018 | 54 | 0.150 |
Why?
|
Acetylation | 4 | 2019 | 521 | 0.150 |
Why?
|
Cytochrome P-450 CYP3A Inhibitors | 1 | 2017 | 28 | 0.150 |
Why?
|
Myelodysplastic-Myeloproliferative Diseases | 1 | 2019 | 115 | 0.150 |
Why?
|
Water-Electrolyte Imbalance | 1 | 2019 | 97 | 0.150 |
Why?
|
Cytoreduction Surgical Procedures | 1 | 2022 | 486 | 0.150 |
Why?
|
Ceramides | 2 | 2008 | 95 | 0.150 |
Why?
|
High-Throughput Screening Assays | 1 | 2019 | 214 | 0.150 |
Why?
|
Synthetic Lethal Mutations | 1 | 2017 | 32 | 0.150 |
Why?
|
Protein-Arginine N-Methyltransferases | 1 | 2019 | 214 | 0.150 |
Why?
|
Multipotent Stem Cells | 1 | 2017 | 50 | 0.150 |
Why?
|
Drug Screening Assays, Antitumor | 4 | 2007 | 567 | 0.150 |
Why?
|
Mitogen-Activated Protein Kinases | 5 | 2006 | 656 | 0.150 |
Why?
|
Leukemia, Prolymphocytic, T-Cell | 1 | 2017 | 44 | 0.150 |
Why?
|
Triterpenes | 3 | 2008 | 65 | 0.150 |
Why?
|
Base Sequence | 7 | 2016 | 4929 | 0.150 |
Why?
|
Metabolic Networks and Pathways | 1 | 2019 | 342 | 0.150 |
Why?
|
Chemotaxis | 2 | 2008 | 144 | 0.150 |
Why?
|
DNA Damage | 4 | 2024 | 1987 | 0.150 |
Why?
|
Acrylates | 1 | 2017 | 31 | 0.150 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2018 | 261 | 0.150 |
Why?
|
Microscopy, Confocal | 3 | 2019 | 676 | 0.150 |
Why?
|
Lymphoma, Follicular | 1 | 2022 | 604 | 0.150 |
Why?
|
Chromatin Immunoprecipitation | 3 | 2017 | 512 | 0.150 |
Why?
|
Epigenesis, Genetic | 3 | 2022 | 1431 | 0.150 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 2019 | 335 | 0.150 |
Why?
|
RNA | 1 | 2022 | 1030 | 0.150 |
Why?
|
HLA Antigens | 2 | 2024 | 566 | 0.150 |
Why?
|
Glutamate Dehydrogenase | 1 | 2016 | 15 | 0.150 |
Why?
|
Hydroxamic Acids | 2 | 2012 | 444 | 0.140 |
Why?
|
Down-Regulation | 7 | 2013 | 2113 | 0.140 |
Why?
|
Bone Marrow Transplantation | 2 | 2013 | 1607 | 0.140 |
Why?
|
Exotoxins | 1 | 2017 | 78 | 0.140 |
Why?
|
Hydrazines | 1 | 2019 | 211 | 0.140 |
Why?
|
Leukemia, Prolymphocytic | 2 | 2007 | 53 | 0.140 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2017 | 87 | 0.140 |
Why?
|
Leukemia, T-Cell | 2 | 2007 | 88 | 0.140 |
Why?
|
Erlotinib Hydrochloride | 1 | 2018 | 390 | 0.140 |
Why?
|
Glutarates | 1 | 2016 | 44 | 0.140 |
Why?
|
DNA (Cytosine-5-)-Methyltransferases | 3 | 2017 | 316 | 0.140 |
Why?
|
Biguanides | 1 | 2016 | 11 | 0.140 |
Why?
|
Trans-Activators | 2 | 2022 | 1624 | 0.140 |
Why?
|
Pyridones | 4 | 2022 | 366 | 0.140 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 1375 | 0.140 |
Why?
|
Single-Chain Antibodies | 1 | 2017 | 64 | 0.140 |
Why?
|
Luciferases | 3 | 2016 | 454 | 0.140 |
Why?
|
RNA Interference | 3 | 2019 | 1411 | 0.140 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 2017 | 174 | 0.140 |
Why?
|
Neutropenia | 3 | 2019 | 987 | 0.140 |
Why?
|
Mice, Inbred BALB C | 6 | 2015 | 2401 | 0.140 |
Why?
|
Leukemia, Erythroblastic, Acute | 1 | 2017 | 119 | 0.140 |
Why?
|
Spinal Cord Diseases | 1 | 2017 | 87 | 0.140 |
Why?
|
Proteome | 2 | 2017 | 577 | 0.140 |
Why?
|
Glycerol-3-Phosphate O-Acyltransferase | 1 | 2015 | 3 | 0.140 |
Why?
|
Pyrimidinones | 4 | 2022 | 320 | 0.140 |
Why?
|
Hyperbilirubinemia | 1 | 2016 | 77 | 0.140 |
Why?
|
Protein Kinase C | 2 | 2011 | 397 | 0.130 |
Why?
|
Tissue Banks | 1 | 2016 | 53 | 0.130 |
Why?
|
STAT5 Transcription Factor | 1 | 2017 | 223 | 0.130 |
Why?
|
Exanthema | 2 | 2019 | 213 | 0.130 |
Why?
|
Leukocyte Common Antigens | 2 | 2019 | 190 | 0.130 |
Why?
|
Alternative Splicing | 2 | 2016 | 595 | 0.130 |
Why?
|
Arginine | 1 | 2019 | 518 | 0.130 |
Why?
|
Receptors, Erythropoietin | 1 | 2016 | 70 | 0.130 |
Why?
|
Gene Order | 1 | 2016 | 111 | 0.130 |
Why?
|
Depsipeptides | 2 | 2007 | 78 | 0.130 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 2 | 2008 | 307 | 0.130 |
Why?
|
Adaptor Proteins, Signal Transducing | 3 | 2015 | 1457 | 0.130 |
Why?
|
Artificial Intelligence | 1 | 2020 | 430 | 0.130 |
Why?
|
Hyperglycemia | 2 | 2012 | 338 | 0.130 |
Why?
|
Bacterial Toxins | 1 | 2017 | 225 | 0.130 |
Why?
|
Receptor, ErbB-2 | 1 | 2006 | 2616 | 0.130 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2017 | 292 | 0.130 |
Why?
|
Heat Shock Transcription Factors | 1 | 2015 | 44 | 0.130 |
Why?
|
Metabolomics | 1 | 2019 | 483 | 0.130 |
Why?
|
Patient Selection | 2 | 2021 | 2115 | 0.130 |
Why?
|
Immunoenzyme Techniques | 4 | 2015 | 1183 | 0.130 |
Why?
|
Acute Coronary Syndrome | 1 | 2019 | 298 | 0.130 |
Why?
|
Naphthoquinones | 1 | 2015 | 19 | 0.130 |
Why?
|
Lactones | 1 | 2016 | 95 | 0.130 |
Why?
|
Cytodiagnosis | 1 | 2016 | 224 | 0.130 |
Why?
|
Nuclear Pore Complex Proteins | 1 | 2015 | 27 | 0.130 |
Why?
|
Delivery of Health Care | 1 | 2022 | 884 | 0.130 |
Why?
|
Antigens, Bacterial | 1 | 2017 | 369 | 0.130 |
Why?
|
Dimerization | 2 | 2006 | 311 | 0.130 |
Why?
|
Neovascularization, Pathologic | 3 | 2009 | 1574 | 0.130 |
Why?
|
Caspase 3 | 5 | 2015 | 480 | 0.130 |
Why?
|
Stomatitis | 1 | 2016 | 187 | 0.130 |
Why?
|
Carbonic Anhydrases | 1 | 2015 | 43 | 0.130 |
Why?
|
Carbonic Anhydrase IX | 1 | 2015 | 37 | 0.130 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2015 | 217 | 0.130 |
Why?
|
Lung Neoplasms | 4 | 2023 | 11816 | 0.130 |
Why?
|
Incidence | 6 | 2024 | 5887 | 0.130 |
Why?
|
Nuclear Receptor Subfamily 4, Group A, Member 1 | 2 | 2012 | 46 | 0.130 |
Why?
|
X-Linked Inhibitor of Apoptosis Protein | 3 | 2011 | 119 | 0.130 |
Why?
|
Esophagitis | 1 | 2016 | 204 | 0.130 |
Why?
|
Infant | 8 | 2022 | 13756 | 0.120 |
Why?
|
Quantitative Trait Loci | 1 | 2017 | 384 | 0.120 |
Why?
|
Immunohistochemistry | 7 | 2019 | 7702 | 0.120 |
Why?
|
Wnt Signaling Pathway | 1 | 2018 | 446 | 0.120 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2012 | 1292 | 0.120 |
Why?
|
Stem Cell Factor | 1 | 2015 | 89 | 0.120 |
Why?
|
Ribosomal Protein S6 Kinases | 1 | 2015 | 118 | 0.120 |
Why?
|
Forkhead Transcription Factors | 3 | 2015 | 770 | 0.120 |
Why?
|
Mesenchymal Stem Cell Transplantation | 2 | 2021 | 197 | 0.120 |
Why?
|
Interleukin-10 | 1 | 2017 | 491 | 0.120 |
Why?
|
Glutamic Acid | 1 | 2016 | 319 | 0.120 |
Why?
|
Mice, Nude | 5 | 2017 | 4343 | 0.120 |
Why?
|
Enterocolitis | 1 | 2015 | 47 | 0.120 |
Why?
|
Phagocytosis | 2 | 2007 | 274 | 0.120 |
Why?
|
Chromosomes, Human | 1 | 2015 | 291 | 0.120 |
Why?
|
Immunoblotting | 2 | 2014 | 898 | 0.120 |
Why?
|
Intubation, Intratracheal | 1 | 2019 | 459 | 0.120 |
Why?
|
3-Hydroxysteroid Dehydrogenases | 1 | 2014 | 7 | 0.120 |
Why?
|
DNA | 1 | 2022 | 2741 | 0.120 |
Why?
|
Hydroxyprostaglandin Dehydrogenases | 1 | 2014 | 11 | 0.120 |
Why?
|
eIF-2 Kinase | 1 | 2015 | 164 | 0.120 |
Why?
|
In Situ Hybridization, Fluorescence | 4 | 2023 | 2258 | 0.120 |
Why?
|
Intensive Care Units | 1 | 2019 | 747 | 0.120 |
Why?
|
Osteonectin | 1 | 2014 | 55 | 0.120 |
Why?
|
Integrin alpha4beta1 | 1 | 2014 | 45 | 0.120 |
Why?
|
Fluorometry | 1 | 2014 | 34 | 0.120 |
Why?
|
Tumor Stem Cell Assay | 2 | 2008 | 232 | 0.120 |
Why?
|
Drug Discovery | 1 | 2017 | 336 | 0.120 |
Why?
|
Protein Structure, Tertiary | 2 | 2008 | 1503 | 0.120 |
Why?
|
Sequence Analysis, DNA | 5 | 2020 | 2506 | 0.120 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1007 | 0.110 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2016 | 185 | 0.110 |
Why?
|
Retinoids | 2 | 2006 | 171 | 0.110 |
Why?
|
Chromones | 3 | 2013 | 120 | 0.110 |
Why?
|
Pruritus | 1 | 2014 | 88 | 0.110 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 123 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-myc | 2 | 2015 | 833 | 0.110 |
Why?
|
Insulin | 4 | 2012 | 1474 | 0.110 |
Why?
|
Necrosis | 1 | 2015 | 597 | 0.110 |
Why?
|
DNA Mutational Analysis | 5 | 2018 | 2311 | 0.110 |
Why?
|
Staining and Labeling | 1 | 2015 | 431 | 0.110 |
Why?
|
Time Factors | 10 | 2019 | 13251 | 0.110 |
Why?
|
Protein Kinase C-alpha | 3 | 2014 | 66 | 0.110 |
Why?
|
Multiple Myeloma | 2 | 2024 | 2235 | 0.110 |
Why?
|
Phenanthrenes | 2 | 2011 | 42 | 0.110 |
Why?
|
Cyclin D1 | 4 | 2012 | 582 | 0.110 |
Why?
|
Adenine | 3 | 2021 | 651 | 0.110 |
Why?
|
Ligands | 4 | 2018 | 1009 | 0.110 |
Why?
|
Protein Conformation | 3 | 2021 | 1271 | 0.110 |
Why?
|
Leukemia, Myelomonocytic, Acute | 2 | 2020 | 72 | 0.110 |
Why?
|
Retinoic Acid Receptor alpha | 2 | 2020 | 95 | 0.110 |
Why?
|
Drug Monitoring | 1 | 2015 | 337 | 0.110 |
Why?
|
Diterpenes | 2 | 2011 | 111 | 0.110 |
Why?
|
Antigens, Neoplasm | 2 | 2021 | 1558 | 0.110 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2015 | 696 | 0.110 |
Why?
|
DNA Repair | 2 | 2024 | 1905 | 0.110 |
Why?
|
Gene Regulatory Networks | 1 | 2017 | 682 | 0.110 |
Why?
|
Predictive Value of Tests | 4 | 2019 | 5030 | 0.110 |
Why?
|
Everolimus | 3 | 2017 | 419 | 0.100 |
Why?
|
Thiazolidinediones | 3 | 2012 | 152 | 0.100 |
Why?
|
Mechanistic Target of Rapamycin Complex 2 | 1 | 2012 | 68 | 0.100 |
Why?
|
Glutathione | 3 | 2019 | 369 | 0.100 |
Why?
|
Bacteria | 1 | 2017 | 623 | 0.100 |
Why?
|
Transplantation, Heterotopic | 1 | 2012 | 42 | 0.100 |
Why?
|
Tumor Suppressor Proteins | 3 | 2006 | 1876 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-raf | 3 | 2012 | 83 | 0.100 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2014 | 509 | 0.100 |
Why?
|
Hematopoiesis, Extramedullary | 1 | 2012 | 41 | 0.100 |
Why?
|
fas Receptor | 3 | 2006 | 193 | 0.100 |
Why?
|
Microscopy, Fluorescence | 2 | 2011 | 774 | 0.100 |
Why?
|
Boronic Acids | 2 | 2010 | 364 | 0.100 |
Why?
|
Maintenance Chemotherapy | 3 | 2021 | 221 | 0.100 |
Why?
|
Breast Neoplasms | 5 | 2013 | 16050 | 0.100 |
Why?
|
Growth Inhibitors | 3 | 2010 | 154 | 0.100 |
Why?
|
PTEN Phosphohydrolase | 1 | 2017 | 999 | 0.100 |
Why?
|
Feasibility Studies | 4 | 2022 | 2362 | 0.100 |
Why?
|
Genetic Predisposition to Disease | 4 | 2020 | 5704 | 0.100 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2012 | 204 | 0.100 |
Why?
|
Hemorrhage | 3 | 2023 | 766 | 0.100 |
Why?
|
Membrane Transport Proteins | 1 | 2012 | 248 | 0.100 |
Why?
|
Herpesvirus 4, Human | 1 | 2015 | 954 | 0.100 |
Why?
|
Lymphocyte Depletion | 1 | 2012 | 290 | 0.100 |
Why?
|
Pancreatic Neoplasms | 4 | 2010 | 5226 | 0.100 |
Why?
|
Transcriptional Activation | 2 | 2006 | 1096 | 0.090 |
Why?
|
Coumarins | 1 | 2010 | 34 | 0.090 |
Why?
|
Bacteremia | 1 | 2017 | 693 | 0.090 |
Why?
|
HLA-DR Antigens | 1 | 2011 | 181 | 0.090 |
Why?
|
Transcription, Genetic | 4 | 2007 | 3148 | 0.090 |
Why?
|
Nitric Oxide | 3 | 2010 | 658 | 0.090 |
Why?
|
Adenosine Triphosphate | 3 | 2022 | 578 | 0.090 |
Why?
|
Coronary Artery Disease | 1 | 2019 | 1093 | 0.090 |
Why?
|
Neoplasm Invasiveness | 3 | 2017 | 4052 | 0.090 |
Why?
|
RUNX1 Translocation Partner 1 Protein | 2 | 2007 | 36 | 0.090 |
Why?
|
Hydroxyurea | 2 | 2022 | 212 | 0.090 |
Why?
|
Cardiovascular Diseases | 1 | 2024 | 2352 | 0.090 |
Why?
|
Interferon-beta | 1 | 2010 | 107 | 0.090 |
Why?
|
Mitochondrial Membrane Transport Proteins | 2 | 2009 | 78 | 0.090 |
Why?
|
Databases, Factual | 3 | 2024 | 2315 | 0.090 |
Why?
|
Case-Control Studies | 5 | 2020 | 6241 | 0.090 |
Why?
|
Cell Lineage | 3 | 2021 | 700 | 0.090 |
Why?
|
Genes, abl | 3 | 2019 | 115 | 0.090 |
Why?
|
Treatment Failure | 3 | 2020 | 1431 | 0.090 |
Why?
|
Oligonucleotides | 1 | 2011 | 231 | 0.090 |
Why?
|
Mice, Inbred C57BL | 6 | 2021 | 7154 | 0.090 |
Why?
|
ADP-ribosyl Cyclase | 2 | 2000 | 33 | 0.090 |
Why?
|
Leptin | 4 | 2013 | 307 | 0.090 |
Why?
|
Cyclins | 3 | 2006 | 466 | 0.090 |
Why?
|
DNA Primers | 3 | 2012 | 1421 | 0.090 |
Why?
|
Diet | 2 | 2024 | 1476 | 0.090 |
Why?
|
Fatigue | 3 | 2022 | 1267 | 0.080 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2010 | 198 | 0.080 |
Why?
|
Diagnosis, Differential | 4 | 2020 | 4845 | 0.080 |
Why?
|
Promoter Regions, Genetic | 4 | 2016 | 3104 | 0.080 |
Why?
|
CD3 Complex | 2 | 2023 | 316 | 0.080 |
Why?
|
United States | 3 | 2024 | 16302 | 0.080 |
Why?
|
Myeloid Cells | 2 | 2023 | 276 | 0.080 |
Why?
|
Mice, Mutant Strains | 2 | 2010 | 638 | 0.080 |
Why?
|
Antibodies, Neutralizing | 1 | 2013 | 569 | 0.080 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 2010 | 230 | 0.080 |
Why?
|
Mitosis | 2 | 2008 | 623 | 0.080 |
Why?
|
Proteolysis | 2 | 2021 | 375 | 0.080 |
Why?
|
Receptors, Tumor Necrosis Factor | 2 | 2006 | 203 | 0.080 |
Why?
|
Metformin | 4 | 2016 | 390 | 0.080 |
Why?
|
STAT Transcription Factors | 2 | 2023 | 81 | 0.080 |
Why?
|
Odds Ratio | 2 | 2011 | 2361 | 0.080 |
Why?
|
AraC Transcription Factor | 1 | 2008 | 6 | 0.080 |
Why?
|
Oxides | 2 | 2021 | 210 | 0.080 |
Why?
|
Europe | 2 | 2021 | 668 | 0.080 |
Why?
|
Caspase 9 | 3 | 2010 | 189 | 0.080 |
Why?
|
Transfection | 3 | 2014 | 2988 | 0.080 |
Why?
|
Lipopolysaccharide Receptors | 1 | 2008 | 88 | 0.080 |
Why?
|
Aerobiosis | 2 | 2021 | 30 | 0.080 |
Why?
|
Sarcoma | 1 | 2019 | 1830 | 0.080 |
Why?
|
Drug Substitution | 2 | 2018 | 87 | 0.080 |
Why?
|
Disease Progression | 4 | 2021 | 6888 | 0.080 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 2 | 2005 | 268 | 0.080 |
Why?
|
Cell Nucleus | 4 | 2007 | 1642 | 0.080 |
Why?
|
Platelet Count | 2 | 2019 | 494 | 0.080 |
Why?
|
CCAAT-Enhancer-Binding Protein-alpha | 1 | 2007 | 22 | 0.080 |
Why?
|
Lymphocyte Count | 2 | 2019 | 489 | 0.070 |
Why?
|
TNF Receptor-Associated Factor 2 | 1 | 2007 | 40 | 0.070 |
Why?
|
DNA, Neoplasm | 4 | 2018 | 1929 | 0.070 |
Why?
|
Oligonucleotide Array Sequence Analysis | 4 | 2015 | 2520 | 0.070 |
Why?
|
Saccharomyces cerevisiae Proteins | 1 | 2001 | 453 | 0.070 |
Why?
|
Mutation, Missense | 3 | 2019 | 1211 | 0.070 |
Why?
|
Chromosome Deletion | 2 | 2022 | 1018 | 0.070 |
Why?
|
Lysine | 2 | 2021 | 428 | 0.070 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 2 | 2005 | 286 | 0.070 |
Why?
|
Cyclin D | 1 | 2006 | 37 | 0.070 |
Why?
|
Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2006 | 27 | 0.070 |
Why?
|
Regulatory-Associated Protein of mTOR | 1 | 2006 | 14 | 0.070 |
Why?
|
Transcription Factor HES-1 | 1 | 2007 | 49 | 0.070 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2005 | 296 | 0.070 |
Why?
|
Receptors, Thyroid Hormone | 1 | 2007 | 93 | 0.070 |
Why?
|
Glucose Transporter Type 1 | 1 | 2006 | 62 | 0.070 |
Why?
|
Academic Medical Centers | 2 | 2022 | 688 | 0.070 |
Why?
|
Mice, Inbred CBA | 2 | 2017 | 78 | 0.070 |
Why?
|
Granulocytes | 1 | 2007 | 226 | 0.070 |
Why?
|
Receptors, Leptin | 3 | 2004 | 65 | 0.070 |
Why?
|
Melphalan | 2 | 2020 | 839 | 0.070 |
Why?
|
Gene Knockdown Techniques | 3 | 2014 | 1082 | 0.070 |
Why?
|
Chemokines, CXC | 1 | 2006 | 122 | 0.070 |
Why?
|
Annexin A5 | 2 | 2006 | 75 | 0.070 |
Why?
|
Parathyroid Hormone | 1 | 2007 | 197 | 0.070 |
Why?
|
Tumor Necrosis Factors | 1 | 2006 | 35 | 0.070 |
Why?
|
Pregnadienes | 1 | 2005 | 2 | 0.070 |
Why?
|
Pregnenediones | 1 | 2005 | 4 | 0.070 |
Why?
|
Binding Sites | 3 | 2019 | 2208 | 0.070 |
Why?
|
Analysis of Variance | 3 | 2015 | 2327 | 0.070 |
Why?
|
Receptors, Leukotriene B4 | 1 | 2005 | 8 | 0.070 |
Why?
|
Comorbidity | 3 | 2022 | 2454 | 0.070 |
Why?
|
Genetic Association Studies | 2 | 2020 | 1090 | 0.070 |
Why?
|
Genome-Wide Association Study | 1 | 2014 | 2339 | 0.070 |
Why?
|
Cell Adhesion | 2 | 2014 | 1016 | 0.070 |
Why?
|
Geriatric Assessment | 2 | 2018 | 291 | 0.070 |
Why?
|
Angiogenesis Inhibitors | 1 | 2013 | 1261 | 0.070 |
Why?
|
Cell Membrane Permeability | 1 | 2006 | 125 | 0.070 |
Why?
|
Receptors, Steroid | 1 | 2007 | 293 | 0.070 |
Why?
|
DNA Fragmentation | 2 | 2005 | 199 | 0.070 |
Why?
|
DNA, Complementary | 1 | 2007 | 880 | 0.060 |
Why?
|
Tetrazoles | 1 | 2006 | 106 | 0.060 |
Why?
|
MAP Kinase Kinase 4 | 1 | 2005 | 143 | 0.060 |
Why?
|
Thiazoles | 2 | 2021 | 730 | 0.060 |
Why?
|
HEK293 Cells | 2 | 2020 | 1512 | 0.060 |
Why?
|
Agar | 1 | 2004 | 26 | 0.060 |
Why?
|
Flavoproteins | 1 | 2004 | 33 | 0.060 |
Why?
|
Apoptosis Inducing Factor | 1 | 2004 | 21 | 0.060 |
Why?
|
Staurosporine | 3 | 2015 | 144 | 0.060 |
Why?
|
I-kappa B Kinase | 1 | 2006 | 251 | 0.060 |
Why?
|
Rituximab | 2 | 2021 | 1551 | 0.060 |
Why?
|
Phosphatidylserines | 1 | 2004 | 70 | 0.060 |
Why?
|
Drug Resistance, Multiple | 2 | 2003 | 210 | 0.060 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2008 | 285 | 0.060 |
Why?
|
Blood Platelets | 2 | 2019 | 741 | 0.060 |
Why?
|
Major Histocompatibility Complex | 1 | 2004 | 95 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-cbl | 1 | 2024 | 40 | 0.060 |
Why?
|
Histological Techniques | 2 | 2015 | 66 | 0.060 |
Why?
|
ARNTL Transcription Factors | 1 | 2024 | 57 | 0.060 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2021 | 1657 | 0.060 |
Why?
|
Proteasome Endopeptidase Complex | 2 | 2021 | 592 | 0.060 |
Why?
|
Sucrose | 1 | 2024 | 63 | 0.060 |
Why?
|
Etoposide | 3 | 2017 | 886 | 0.060 |
Why?
|
RNA, Neoplasm | 2 | 2006 | 797 | 0.060 |
Why?
|
Reproducibility of Results | 3 | 2019 | 6192 | 0.060 |
Why?
|
Drug Interactions | 2 | 2004 | 573 | 0.060 |
Why?
|
Georgia | 1 | 2023 | 55 | 0.060 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2007 | 505 | 0.060 |
Why?
|
Metaphase | 1 | 2003 | 106 | 0.060 |
Why?
|
Cyclin E | 1 | 2005 | 273 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 1 | 2007 | 471 | 0.060 |
Why?
|
Cell Growth Processes | 3 | 2010 | 342 | 0.060 |
Why?
|
Immunotherapy | 3 | 2022 | 3480 | 0.060 |
Why?
|
Computational Biology | 2 | 2020 | 1298 | 0.060 |
Why?
|
G1 Phase | 3 | 2009 | 292 | 0.060 |
Why?
|
G2 Phase Cell Cycle Checkpoints | 1 | 2023 | 77 | 0.060 |
Why?
|
Neoplasms, Experimental | 2 | 2019 | 749 | 0.050 |
Why?
|
Haplotypes | 2 | 2018 | 883 | 0.050 |
Why?
|
Sequence Analysis, RNA | 2 | 2017 | 688 | 0.050 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2021 | 1059 | 0.050 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2007 | 623 | 0.050 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2008 | 621 | 0.050 |
Why?
|
Sezary Syndrome | 1 | 2004 | 163 | 0.050 |
Why?
|
New York City | 1 | 2022 | 78 | 0.050 |
Why?
|
Culture Media, Serum-Free | 1 | 2002 | 77 | 0.050 |
Why?
|
K562 Cells | 3 | 2008 | 340 | 0.050 |
Why?
|
Insulin, Long-Acting | 2 | 2012 | 18 | 0.050 |
Why?
|
Insulin Glargine | 2 | 2012 | 20 | 0.050 |
Why?
|
Plasmids | 1 | 2004 | 843 | 0.050 |
Why?
|
Neoplasm Metastasis | 1 | 2013 | 5238 | 0.050 |
Why?
|
Confidence Intervals | 2 | 2018 | 769 | 0.050 |
Why?
|
Glycogen Synthase Kinase 3 | 1 | 2023 | 161 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 2 | 2017 | 7959 | 0.050 |
Why?
|
CTLA-4 Antigen | 2 | 2018 | 665 | 0.050 |
Why?
|
Income | 1 | 2023 | 235 | 0.050 |
Why?
|
Oxazoles | 1 | 2022 | 63 | 0.050 |
Why?
|
Nausea | 2 | 2015 | 535 | 0.050 |
Why?
|
North America | 1 | 2023 | 340 | 0.050 |
Why?
|
Estradiol | 1 | 2005 | 761 | 0.050 |
Why?
|
Electron Transport Complex I | 1 | 2022 | 61 | 0.050 |
Why?
|
Pandemics | 2 | 2022 | 1625 | 0.050 |
Why?
|
Antiviral Agents | 2 | 2022 | 1260 | 0.050 |
Why?
|
beta 2-Microglobulin | 1 | 2002 | 184 | 0.050 |
Why?
|
Recombinant Proteins | 3 | 2017 | 2941 | 0.050 |
Why?
|
Alanine Transaminase | 1 | 2022 | 240 | 0.050 |
Why?
|
Precision Medicine | 2 | 2022 | 1197 | 0.050 |
Why?
|
Immunoprecipitation | 2 | 2015 | 590 | 0.050 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2023 | 321 | 0.050 |
Why?
|
Frail Elderly | 1 | 2022 | 123 | 0.050 |
Why?
|
Fibrinolytic Agents | 1 | 2004 | 345 | 0.050 |
Why?
|
Polymerase Chain Reaction | 3 | 2016 | 3234 | 0.050 |
Why?
|
B7 Antigens | 1 | 2022 | 85 | 0.050 |
Why?
|
Granzymes | 1 | 2021 | 92 | 0.050 |
Why?
|
Minority Groups | 1 | 2024 | 328 | 0.050 |
Why?
|
Head and Neck Neoplasms | 1 | 2017 | 4072 | 0.050 |
Why?
|
Splicing Factor U2AF | 1 | 2021 | 48 | 0.050 |
Why?
|
Lentivirus | 2 | 2015 | 171 | 0.050 |
Why?
|
Community Health Services | 1 | 2022 | 131 | 0.050 |
Why?
|
Lymphocyte Culture Test, Mixed | 2 | 2014 | 92 | 0.050 |
Why?
|
Gender Identity | 1 | 2021 | 81 | 0.050 |
Why?
|
Serine-Arginine Splicing Factors | 1 | 2021 | 88 | 0.050 |
Why?
|
Ubiquitin-Conjugating Enzymes | 1 | 2021 | 94 | 0.050 |
Why?
|
Phosphate-Binding Proteins | 1 | 2020 | 18 | 0.050 |
Why?
|
Calcium | 2 | 2006 | 1556 | 0.050 |
Why?
|
DNA Helicases | 1 | 2024 | 450 | 0.050 |
Why?
|
Furans | 2 | 2014 | 106 | 0.050 |
Why?
|
Karyotyping | 2 | 2017 | 1022 | 0.050 |
Why?
|
Mycosis Fungoides | 1 | 2004 | 330 | 0.050 |
Why?
|
Gene Fusion | 1 | 2022 | 212 | 0.050 |
Why?
|
Standard of Care | 1 | 2023 | 267 | 0.050 |
Why?
|
Sex Factors | 2 | 2017 | 2215 | 0.050 |
Why?
|
CCAAT-Enhancer-Binding Proteins | 1 | 2021 | 104 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2017 | 5531 | 0.050 |
Why?
|
Urate Oxidase | 1 | 2020 | 35 | 0.050 |
Why?
|
Epoxy Compounds | 2 | 2011 | 56 | 0.050 |
Why?
|
Receptor, Notch1 | 1 | 2022 | 221 | 0.050 |
Why?
|
Promyelocytic Leukemia Protein | 1 | 2020 | 56 | 0.050 |
Why?
|
Phosphorus | 1 | 2020 | 66 | 0.050 |
Why?
|
Antigen Presentation | 1 | 2021 | 283 | 0.050 |
Why?
|
Leukocytosis | 1 | 2020 | 114 | 0.050 |
Why?
|
Aldehyde Dehydrogenase | 1 | 2020 | 103 | 0.050 |
Why?
|
Intention to Treat Analysis | 1 | 2020 | 133 | 0.050 |
Why?
|
Macrophages | 1 | 2007 | 1372 | 0.050 |
Why?
|
Doxycycline | 1 | 2021 | 185 | 0.040 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2020 | 146 | 0.040 |
Why?
|
Leukopenia | 1 | 2020 | 148 | 0.040 |
Why?
|
Uric Acid | 1 | 2020 | 116 | 0.040 |
Why?
|
Fluorescent Dyes | 1 | 2002 | 465 | 0.040 |
Why?
|
Socioeconomic Factors | 1 | 2024 | 1263 | 0.040 |
Why?
|
Graft Survival | 1 | 2004 | 1088 | 0.040 |
Why?
|
Gene Knockout Techniques | 1 | 2021 | 278 | 0.040 |
Why?
|
Survivorship | 1 | 2020 | 116 | 0.040 |
Why?
|
Small Molecule Libraries | 1 | 2021 | 195 | 0.040 |
Why?
|
Multigene Family | 1 | 2021 | 428 | 0.040 |
Why?
|
Quality Control | 1 | 2021 | 460 | 0.040 |
Why?
|
Time | 1 | 2020 | 182 | 0.040 |
Why?
|
Nerve Tissue Proteins | 1 | 2007 | 1508 | 0.040 |
Why?
|
Fluid Therapy | 1 | 2020 | 184 | 0.040 |
Why?
|
Immunotoxins | 1 | 2000 | 117 | 0.040 |
Why?
|
Leukocytes, Mononuclear | 1 | 2022 | 707 | 0.040 |
Why?
|
Ataxia Telangiectasia Mutated Proteins | 2 | 2015 | 434 | 0.040 |
Why?
|
Immunity, Cellular | 1 | 2021 | 428 | 0.040 |
Why?
|
Gene Duplication | 2 | 2014 | 433 | 0.040 |
Why?
|
Cancer Care Facilities | 2 | 2018 | 905 | 0.040 |
Why?
|
Diamines | 1 | 2019 | 25 | 0.040 |
Why?
|
Thy-1 Antigens | 1 | 2019 | 48 | 0.040 |
Why?
|
Cell Tracking | 1 | 2019 | 38 | 0.040 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2020 | 334 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2008 | 531 | 0.040 |
Why?
|
CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 1999 | 39 | 0.040 |
Why?
|
Stimulation, Chemical | 1 | 1998 | 96 | 0.040 |
Why?
|
Ubiquitination | 1 | 2021 | 579 | 0.040 |
Why?
|
Histone Deacetylases | 2 | 2015 | 365 | 0.040 |
Why?
|
Dyspnea | 1 | 2022 | 425 | 0.040 |
Why?
|
Genes, cdc | 1 | 2018 | 83 | 0.040 |
Why?
|
Isoenzymes | 1 | 2021 | 633 | 0.040 |
Why?
|
Diploidy | 1 | 2018 | 112 | 0.040 |
Why?
|
Serum Albumin | 1 | 2019 | 249 | 0.040 |
Why?
|
Hodgkin Disease | 1 | 2007 | 1457 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2009 | 1427 | 0.040 |
Why?
|
Fas Ligand Protein | 1 | 1999 | 153 | 0.040 |
Why?
|
Inflammation | 2 | 2023 | 2567 | 0.040 |
Why?
|
Texas | 2 | 2021 | 6454 | 0.040 |
Why?
|
Azepines | 1 | 2019 | 128 | 0.040 |
Why?
|
Liposomes | 1 | 2000 | 690 | 0.040 |
Why?
|
Receptors, KIR | 1 | 2018 | 62 | 0.040 |
Why?
|
Autoimmune Diseases | 1 | 2021 | 418 | 0.040 |
Why?
|
Protein Domains | 1 | 2019 | 335 | 0.040 |
Why?
|
Mutation Rate | 1 | 2019 | 230 | 0.040 |
Why?
|
Prednisone | 1 | 2021 | 996 | 0.040 |
Why?
|
Receptors, Estrogen | 1 | 2005 | 2122 | 0.040 |
Why?
|
Oxygen Consumption | 1 | 2019 | 396 | 0.040 |
Why?
|
Chromosomes | 1 | 2019 | 251 | 0.040 |
Why?
|
Hyaluronan Receptors | 1 | 2019 | 255 | 0.040 |
Why?
|
Patient Transfer | 1 | 2019 | 139 | 0.040 |
Why?
|
Nucleotides | 1 | 2018 | 164 | 0.040 |
Why?
|
RNA-Binding Proteins | 1 | 2023 | 1006 | 0.040 |
Why?
|
Inhibitory Concentration 50 | 2 | 2012 | 292 | 0.040 |
Why?
|
Gene Deletion | 2 | 2017 | 1472 | 0.040 |
Why?
|
Salmonella typhimurium | 1 | 2017 | 70 | 0.040 |
Why?
|
DNA, Mitochondrial | 1 | 2019 | 318 | 0.040 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2018 | 314 | 0.040 |
Why?
|
CRISPR-Cas Systems | 1 | 2021 | 353 | 0.040 |
Why?
|
Subacute Combined Degeneration | 1 | 2017 | 16 | 0.040 |
Why?
|
Naphthyridines | 1 | 2017 | 42 | 0.040 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 2 | 2010 | 210 | 0.040 |
Why?
|
Receptor, Cannabinoid, CB2 | 1 | 2017 | 17 | 0.040 |
Why?
|
Leukocyte Count | 1 | 2018 | 705 | 0.040 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2017 | 1589 | 0.040 |
Why?
|
Genome, Human | 2 | 2017 | 1896 | 0.040 |
Why?
|
Chromosome Banding | 1 | 2017 | 259 | 0.040 |
Why?
|
Ikaros Transcription Factor | 1 | 2017 | 54 | 0.040 |
Why?
|
Safety | 1 | 2018 | 471 | 0.040 |
Why?
|
Platinum Compounds | 1 | 2017 | 129 | 0.040 |
Why?
|
Mitoxantrone | 1 | 2017 | 219 | 0.040 |
Why?
|
MEF2 Transcription Factors | 1 | 2016 | 49 | 0.040 |
Why?
|
Citric Acid Cycle | 1 | 2017 | 87 | 0.040 |
Why?
|
Phenformin | 1 | 2016 | 7 | 0.040 |
Why?
|
Single-Blind Method | 1 | 2018 | 418 | 0.040 |
Why?
|
Evolution, Molecular | 1 | 2021 | 854 | 0.040 |
Why?
|
Autografts | 1 | 2017 | 169 | 0.040 |
Why?
|
Colonic Neoplasms | 1 | 2005 | 1429 | 0.040 |
Why?
|
Rotenone | 1 | 2016 | 35 | 0.040 |
Why?
|
Models, Molecular | 1 | 2021 | 1766 | 0.030 |
Why?
|
Cell Count | 1 | 2017 | 512 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2019 | 629 | 0.030 |
Why?
|
Mitochondrial Proteins | 2 | 2009 | 380 | 0.030 |
Why?
|
Rare Diseases | 1 | 2019 | 358 | 0.030 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2017 | 86 | 0.030 |
Why?
|
Metabolome | 1 | 2019 | 350 | 0.030 |
Why?
|
Protons | 1 | 2019 | 476 | 0.030 |
Why?
|
Injections, Spinal | 1 | 2017 | 261 | 0.030 |
Why?
|
Homocysteine | 1 | 2017 | 147 | 0.030 |
Why?
|
Health Services Accessibility | 1 | 2022 | 816 | 0.030 |
Why?
|
Polycomb Repressive Complex 1 | 1 | 2016 | 86 | 0.030 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2021 | 866 | 0.030 |
Why?
|
NIH 3T3 Cells | 1 | 2016 | 264 | 0.030 |
Why?
|
Models, Genetic | 1 | 2020 | 1129 | 0.030 |
Why?
|
Janus Kinase 1 | 1 | 2017 | 125 | 0.030 |
Why?
|
Bone Marrow Examination | 1 | 2016 | 154 | 0.030 |
Why?
|
False Positive Reactions | 1 | 2017 | 361 | 0.030 |
Why?
|
Precursor Cells, T-Lymphoid | 1 | 2016 | 23 | 0.030 |
Why?
|
Interleukin-12 | 1 | 2017 | 265 | 0.030 |
Why?
|
Colitis | 1 | 2019 | 338 | 0.030 |
Why?
|
Antigens, CD1 | 1 | 2016 | 51 | 0.030 |
Why?
|
Receptor Cross-Talk | 1 | 2016 | 80 | 0.030 |
Why?
|
Karyopherins | 1 | 2017 | 135 | 0.030 |
Why?
|
Cardiolipins | 2 | 2006 | 34 | 0.030 |
Why?
|
Telemedicine | 1 | 2022 | 536 | 0.030 |
Why?
|
Oncogenes | 1 | 2019 | 677 | 0.030 |
Why?
|
Azure Stains | 1 | 2015 | 11 | 0.030 |
Why?
|
Receptors, Glucocorticoid | 1 | 2017 | 198 | 0.030 |
Why?
|
Isoquinolines | 1 | 2016 | 119 | 0.030 |
Why?
|
Dacarbazine | 1 | 2018 | 488 | 0.030 |
Why?
|
Systems Integration | 1 | 2015 | 77 | 0.030 |
Why?
|
Poly I-C | 1 | 2015 | 30 | 0.030 |
Why?
|
Protein Transport | 1 | 2018 | 745 | 0.030 |
Why?
|
Eosine Yellowish-(YS) | 1 | 2015 | 33 | 0.030 |
Why?
|
Cost of Illness | 1 | 2019 | 513 | 0.030 |
Why?
|
Tetrahydronaphthalenes | 2 | 2007 | 117 | 0.030 |
Why?
|
Mice, Inbred Strains | 1 | 2016 | 523 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2020 | 1081 | 0.030 |
Why?
|
Injections, Intraperitoneal | 1 | 2015 | 200 | 0.030 |
Why?
|
Codon | 1 | 2015 | 245 | 0.030 |
Why?
|
Drug Design | 1 | 2017 | 383 | 0.030 |
Why?
|
Neoplasm Staging | 3 | 2017 | 13879 | 0.030 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2015 | 256 | 0.030 |
Why?
|
Age of Onset | 1 | 2017 | 841 | 0.030 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2019 | 611 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2018 | 1409 | 0.030 |
Why?
|
Neoplasm Grading | 1 | 2019 | 1807 | 0.030 |
Why?
|
Molecular Sequence Data | 2 | 2016 | 6123 | 0.030 |
Why?
|
Antigens, CD20 | 1 | 2015 | 206 | 0.030 |
Why?
|
Chronic Disease | 1 | 2020 | 1855 | 0.030 |
Why?
|
Thioguanine | 1 | 2014 | 69 | 0.030 |
Why?
|
Homeostasis | 1 | 2019 | 946 | 0.030 |
Why?
|
Propylene Glycols | 1 | 2014 | 38 | 0.030 |
Why?
|
Random Allocation | 1 | 2016 | 717 | 0.030 |
Why?
|
Double-Blind Method | 1 | 2020 | 2661 | 0.030 |
Why?
|
Sphingosine | 1 | 2014 | 59 | 0.030 |
Why?
|
CpG Islands | 1 | 2017 | 654 | 0.030 |
Why?
|
Drug Resistance | 1 | 2016 | 599 | 0.030 |
Why?
|
Aldo-Keto Reductase Family 1 Member C3 | 1 | 2014 | 2 | 0.030 |
Why?
|
Interleukin-3 | 1 | 2014 | 97 | 0.030 |
Why?
|
Fingolimod Hydrochloride | 1 | 2014 | 50 | 0.030 |
Why?
|
Folic Acid | 1 | 2017 | 372 | 0.030 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2015 | 745 | 0.030 |
Why?
|
Diphtheria Toxin | 1 | 2014 | 83 | 0.030 |
Why?
|
Interleukin-2 | 1 | 2017 | 851 | 0.030 |
Why?
|
Inpatients | 1 | 2019 | 701 | 0.030 |
Why?
|
Carbazoles | 1 | 2014 | 88 | 0.030 |
Why?
|
Molecular Dynamics Simulation | 1 | 2014 | 139 | 0.030 |
Why?
|
Antigens, Ly | 1 | 2013 | 50 | 0.030 |
Why?
|
Gastrointestinal Diseases | 1 | 2018 | 596 | 0.030 |
Why?
|
Genes, Neoplasm | 1 | 2015 | 328 | 0.030 |
Why?
|
YY1 Transcription Factor | 1 | 2013 | 18 | 0.030 |
Why?
|
Cell Line, Transformed | 1 | 2014 | 397 | 0.030 |
Why?
|
Gene Editing | 1 | 2016 | 228 | 0.030 |
Why?
|
Cell Transplantation | 1 | 2013 | 81 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2016 | 1082 | 0.030 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2017 | 668 | 0.030 |
Why?
|
Lipid Metabolism | 1 | 2017 | 487 | 0.030 |
Why?
|
Flavonoids | 2 | 2007 | 200 | 0.030 |
Why?
|
Benzopyrans | 2 | 2004 | 41 | 0.030 |
Why?
|
Catalytic Domain | 1 | 2014 | 307 | 0.030 |
Why?
|
HCT116 Cells | 1 | 2014 | 353 | 0.030 |
Why?
|
Cytoplasm | 2 | 2005 | 652 | 0.030 |
Why?
|
Sp1 Transcription Factor | 1 | 2014 | 190 | 0.030 |
Why?
|
Hospitalization | 1 | 2022 | 2208 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2017 | 630 | 0.030 |
Why?
|
Hospital Mortality | 1 | 2019 | 1405 | 0.030 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2014 | 620 | 0.030 |
Why?
|
Protein Interaction Domains and Motifs | 1 | 2014 | 281 | 0.030 |
Why?
|
Insulin Aspart | 1 | 2012 | 6 | 0.030 |
Why?
|
Carcinoma | 1 | 2004 | 2600 | 0.030 |
Why?
|
Substrate Specificity | 1 | 2014 | 559 | 0.030 |
Why?
|
Medical Records | 1 | 2014 | 425 | 0.030 |
Why?
|
Stents | 1 | 2019 | 1150 | 0.030 |
Why?
|
Oxidative Stress | 1 | 2019 | 1158 | 0.030 |
Why?
|
bcl-Associated Death Protein | 2 | 2004 | 24 | 0.030 |
Why?
|
Interleukin Receptor Common gamma Subunit | 1 | 2012 | 47 | 0.030 |
Why?
|
Urea | 1 | 2014 | 290 | 0.030 |
Why?
|
Genetic Loci | 1 | 2014 | 500 | 0.030 |
Why?
|
Abnormal Karyotype | 1 | 2012 | 100 | 0.030 |
Why?
|
Genomic Instability | 1 | 2015 | 525 | 0.030 |
Why?
|
C-Peptide | 1 | 2012 | 116 | 0.030 |
Why?
|
NAD(P)H Dehydrogenase (Quinone) | 1 | 2012 | 60 | 0.030 |
Why?
|
Leukocytes | 1 | 2014 | 423 | 0.020 |
Why?
|
Protein Kinase C beta | 1 | 2011 | 35 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2013 | 484 | 0.020 |
Why?
|
Cell Separation | 1 | 2013 | 598 | 0.020 |
Why?
|
Internet | 1 | 2016 | 729 | 0.020 |
Why?
|
Replication Protein C | 1 | 2001 | 19 | 0.020 |
Why?
|
Atrial Fibrillation | 1 | 2019 | 799 | 0.020 |
Why?
|
Drug Eruptions | 1 | 2013 | 268 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2015 | 1025 | 0.020 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2011 | 220 | 0.020 |
Why?
|
Prevalence | 1 | 2019 | 3396 | 0.020 |
Why?
|
Drug Dosage Calculations | 1 | 2011 | 50 | 0.020 |
Why?
|
Green Fluorescent Proteins | 1 | 2013 | 701 | 0.020 |
Why?
|
Cell- and Tissue-Based Therapy | 1 | 2013 | 387 | 0.020 |
Why?
|
Species Specificity | 1 | 2012 | 777 | 0.020 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2001 | 112 | 0.020 |
Why?
|
Oncogene Protein v-akt | 1 | 2010 | 102 | 0.020 |
Why?
|
Acetyl-CoA Carboxylase | 1 | 2010 | 56 | 0.020 |
Why?
|
Bone and Bones | 1 | 2014 | 604 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2016 | 2048 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 2009 | 7901 | 0.020 |
Why?
|
Glycoproteins | 1 | 2014 | 763 | 0.020 |
Why?
|
Osteogenesis | 1 | 2012 | 262 | 0.020 |
Why?
|
Fatty Acids, Nonesterified | 1 | 2010 | 160 | 0.020 |
Why?
|
Uncoupling Protein 2 | 1 | 2009 | 27 | 0.020 |
Why?
|
Fatty Acid Synthases | 1 | 2009 | 26 | 0.020 |
Why?
|
ROC Curve | 1 | 2013 | 1224 | 0.020 |
Why?
|
beta Catenin | 1 | 2014 | 697 | 0.020 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2012 | 261 | 0.020 |
Why?
|
Forkhead Box Protein O3 | 1 | 2010 | 112 | 0.020 |
Why?
|
Cysteine Proteinase Inhibitors | 1 | 2010 | 93 | 0.020 |
Why?
|
Cell Membrane | 1 | 2013 | 861 | 0.020 |
Why?
|
Logistic Models | 1 | 2017 | 3519 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2016 | 4278 | 0.020 |
Why?
|
Bleomycin | 1 | 2001 | 478 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2016 | 1533 | 0.020 |
Why?
|
Models, Animal | 1 | 2012 | 692 | 0.020 |
Why?
|
Causality | 1 | 2009 | 183 | 0.020 |
Why?
|
Electronic Health Records | 1 | 2017 | 969 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2006 | 5936 | 0.020 |
Why?
|
Ion Channels | 1 | 2009 | 226 | 0.020 |
Why?
|
Transgenes | 1 | 2010 | 569 | 0.020 |
Why?
|
Research Design | 1 | 2016 | 1598 | 0.020 |
Why?
|
Quality of Life | 1 | 2022 | 4719 | 0.020 |
Why?
|
Aurora Kinases | 1 | 2008 | 194 | 0.020 |
Why?
|
Ovarian Neoplasms | 1 | 2004 | 4730 | 0.020 |
Why?
|
Triglycerides | 1 | 2010 | 621 | 0.020 |
Why?
|
Sex Distribution | 1 | 2009 | 510 | 0.020 |
Why?
|
Nicotinic Acids | 1 | 2007 | 35 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2014 | 1076 | 0.020 |
Why?
|
Luciferases, Renilla | 1 | 2007 | 10 | 0.020 |
Why?
|
Eukaryotic Initiation Factor-4E | 1 | 2007 | 95 | 0.020 |
Why?
|
Fenretinide | 1 | 2007 | 98 | 0.020 |
Why?
|
Blood Glucose | 1 | 2012 | 1269 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2023 | 7732 | 0.020 |
Why?
|
Age Distribution | 1 | 2009 | 715 | 0.020 |
Why?
|
Probability | 1 | 2009 | 889 | 0.020 |
Why?
|
Filgrastim | 1 | 2007 | 191 | 0.020 |
Why?
|
Eukaryotic Initiation Factor-2 | 1 | 2007 | 94 | 0.020 |
Why?
|
Response Elements | 1 | 2007 | 197 | 0.020 |
Why?
|
Mitochondria, Liver | 1 | 2007 | 52 | 0.020 |
Why?
|
Reference Values | 1 | 2009 | 1129 | 0.020 |
Why?
|
Fatty Acids, Unsaturated | 1 | 2007 | 96 | 0.020 |
Why?
|
Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2006 | 19 | 0.020 |
Why?
|
TNF Receptor-Associated Death Domain Protein | 1 | 2006 | 7 | 0.020 |
Why?
|
3-Phosphoinositide-Dependent Protein Kinases | 1 | 2006 | 40 | 0.020 |
Why?
|
G2 Phase | 1 | 2006 | 213 | 0.020 |
Why?
|
Sphingolipids | 1 | 2006 | 39 | 0.020 |
Why?
|
Heme Oxygenase (Decyclizing) | 1 | 2005 | 20 | 0.020 |
Why?
|
Isomerism | 1 | 2005 | 63 | 0.020 |
Why?
|
Acetylcysteine | 1 | 2007 | 147 | 0.020 |
Why?
|
S Phase | 1 | 2006 | 285 | 0.020 |
Why?
|
Cyclosporine | 1 | 2007 | 282 | 0.020 |
Why?
|
Intracellular Membranes | 1 | 2006 | 107 | 0.020 |
Why?
|
Biotinylation | 1 | 2005 | 47 | 0.020 |
Why?
|
Genes, MDR | 1 | 2005 | 42 | 0.020 |
Why?
|
Mutant Proteins | 1 | 2006 | 236 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2019 | 8534 | 0.020 |
Why?
|
Sulfhydryl Compounds | 1 | 2005 | 70 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2008 | 1079 | 0.020 |
Why?
|
Adipose Tissue | 1 | 2010 | 775 | 0.020 |
Why?
|
Models, Chemical | 1 | 2005 | 186 | 0.020 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2006 | 320 | 0.020 |
Why?
|
Actins | 1 | 2008 | 614 | 0.020 |
Why?
|
Calcimycin | 1 | 2004 | 48 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2015 | 4460 | 0.020 |
Why?
|
Ionophores | 1 | 2004 | 24 | 0.020 |
Why?
|
Spleen | 1 | 2007 | 692 | 0.020 |
Why?
|
Cytochromes c | 1 | 2004 | 118 | 0.020 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2006 | 368 | 0.020 |
Why?
|
Subcellular Fractions | 1 | 2004 | 200 | 0.010 |
Why?
|
Cyclooxygenase 2 | 1 | 2006 | 493 | 0.010 |
Why?
|
Protein Processing, Post-Translational | 1 | 2007 | 802 | 0.010 |
Why?
|
Protein Biosynthesis | 1 | 2007 | 913 | 0.010 |
Why?
|
Progesterone | 1 | 2005 | 528 | 0.010 |
Why?
|
Muscle, Skeletal | 1 | 2010 | 1328 | 0.010 |
Why?
|
Genetic Therapy | 1 | 2010 | 1630 | 0.010 |
Why?
|
Antibodies | 1 | 2006 | 842 | 0.010 |
Why?
|
Phosphoprotein Phosphatases | 1 | 2004 | 217 | 0.010 |
Why?
|
Retroviridae | 1 | 2003 | 323 | 0.010 |
Why?
|
Antioxidants | 1 | 2005 | 522 | 0.010 |
Why?
|
Anticarcinogenic Agents | 1 | 2004 | 366 | 0.010 |
Why?
|
Transplantation, Autologous | 1 | 2007 | 1978 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2007 | 2116 | 0.010 |
Why?
|
Genetic Vectors | 1 | 2007 | 1712 | 0.010 |
Why?
|
Thyroid Neoplasms | 1 | 2012 | 1887 | 0.010 |
Why?
|
Oligonucleotides, Antisense | 1 | 2002 | 246 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 1506 | 0.010 |
Why?
|
Biopsy | 1 | 2008 | 3483 | 0.010 |
Why?
|
Phosphoserine | 1 | 1999 | 109 | 0.010 |
Why?
|
Carcinoma, Renal Cell | 1 | 2012 | 2387 | 0.010 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2004 | 881 | 0.010 |
Why?
|
Lymphocytes | 1 | 2004 | 1237 | 0.010 |
Why?
|
Immunocompromised Host | 1 | 2003 | 708 | 0.010 |
Why?
|
Kidney Neoplasms | 1 | 2012 | 3097 | 0.010 |
Why?
|
Testosterone | 1 | 2003 | 630 | 0.010 |
Why?
|
Rats | 1 | 2007 | 6198 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2012 | 3693 | 0.010 |
Why?
|
Melanoma | 1 | 2012 | 5444 | 0.010 |
Why?
|